TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from SanBio Co ( (JP:4592) ) is now available.
SanBio Co., Ltd. has revised its consolidated earnings forecast for the fiscal year ending January 2026, indicating a greater than expected loss. The revision is attributed to increased manufacturing expenses for future clinical trials and the launch of AKUUGO following regulatory approval, as well as foreign exchange losses and deferred tax liabilities impacting net income.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen2100.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on the development of regenerative cell medicines. The company is known for its innovative therapies aimed at treating neurological disorders and other medical conditions.
Average Trading Volume: 2,887,422
Technical Sentiment Signal: Buy
Current Market Cap: Yen170.1B
For detailed information about 4592 stock, go to TipRanks’ Stock Analysis page.